Story: The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. Portion of the biotech industry without exposure to the full risks of the of drug approval process. Strong double-digit growth. COVID has a overall effect of increasing demand for Repligen products that helps make the vaccines and therapeutic drugs designed to combat the disease. Earnings report at Nov 5.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.